Physician profile
Scott Rojas
NPI 1285609784
$59,097.01
in general payments reported to CMS, 2019-2025
29 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $8,504 · 2021: $1,500 · 2022: $1,210 · 2023: $2,616 · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $5,337 · Travel and Lodging: $1,711 · Consulting Fee: $1,380 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,660.00 |
| Food and Beverage | $5,337.39 |
| Travel and Lodging | $1,710.79 |
| Consulting Fee | $1,380.00 |
| Education | $141.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,154.05 | 2019-2025 | Biktarvy, Veklury |
| Insmed, INC. | $17,923.74 | 2019-2025 | Arikayce, Brinsupri |
| Allergan, INC. | $8,005.91 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $3,629.23 | 2019-2025 | Nuzyra |
| Abbvie INC. | $1,897.23 | 2021-2025 | Avycaz, Dalvance, Mavyret |
| Ferring Pharmaceuticals INC. | $1,441.07 | 2023-2025 | Rebyota |
| Viiv Healthcare Company | $1,080.33 | 2019-2025 | Dovato, Apretude, Rukobia |
| Merck Sharp & Dohme LLC | $527.93 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Cumberland Pharmaceuticals, INC. | $461.82 | 2021-2025 | Vibativ |
| Melinta Therapeutics, LLC | $330.48 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Theratechnologies INC. | $287.48 | 2019-2024 | Trogarzo, Egrifta, Egrifta Sv |
| Shionogi INC | $271.77 | 2020-2025 | Fetroja |
| Octapharma USA, INC. | $215.71 | 2020-2025 | Octagam Immune Globulin (Human), Cutaquig, Panzyga |
| La Jolla Pharmaceutical Company | $163.37 | 2021-2025 | Zevtera |
| Astellas Pharma US INC | $104.52 | 2023-2024 | Cresemba |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $99.00 | 2022 | |
| Janssen Biotech, INC. | $69.58 | 2019-2022 | |
| Emd Serono, INC. | $60.14 | 2021-2025 | |
| Kerecis Limited | $58.05 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Tetraphase Pharmaceuticals, INC. | $47.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $47.23 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $45.29 | 2024 | |
| Napo Pharmaceuticals INC | $39.18 | 2021-2025 | Mytesi |
| Pfizer INC. | $35.92 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.38 | 2024 | Hyqvia |
| Shire North American Group INC | $18.43 | 2019 | |
| Exact Sciences Corporation | $15.54 | 2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.